Authors
Latest:
Patients With Esophageal Squamous Cell Carcinoma Respond to Camrelizumab/Apatinib Combo in Second-Line SettingData presented at the 2021 Gastrointestinal Cancers Symposium shows promise for the combination of camrelizumab plus apatinib for previously treated patients with esophageal squamous cell carcinoma.
Latest:
Mounzer Agha, MD, Reviews the Safety Profile of Ciltacabtagene Autoleucel in Multiple MyelomaDuring a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.
Latest:
Evaluation and Management of Testicular Cancer After Late RelapseThe clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
Latest:
‘Definitive’ Data Support Radiation Omission in Advanced Endometrial CancerThe addition of radiation to chemotherapy did not improve overall survival in patients with advanced endometrial cancer, according to an expert from Northwestern Medicine.
Latest:
Closing Thoughts: Key Messages for Clinicians and Patients in the Treatment of HER2+ Breast CancerPanelists discuss advice for nurses collaborating with oncologists in treating patients with HER2+ breast cancer, as well as closing messages for patients receiving treatment and clinicians involved in the care of those with advanced HER2+ breast cancer.
Latest:
Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer OrganizationsAlthough female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.
Latest:
Profilin 1 Protein and Its Implications for CancersProfilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic LeukemiaRachel Rau, MD, gives her perspective on the use of asparaginase treatments for pediatric patients with acute lymphocytic leukemia.
Latest:
Patient-Centered Approaches in EGFR-Mutated NSCLCPanelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Latest:
Expert Commentary on the Product Profile of Loncastuximab TesirineIn an interview with ONCOLOGY®, Keith Hecht, PharmD, offers a comprehensive review of real-world treatment considerations of loncastuximab tesirine as therapy for patients with diffuse large B-cell lymphoma.
Latest:
COLOMATE Challenge to Overcome Resistance in Metastatic Colorectal CancerTakayuki Yoshino, MD, PhD gives his perspective on the COLMATE trial and what it's done to help patients overcome colorectal cancer.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsThe aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
Latest:
Survival Boost Noted With Addition of Durvalumab to Chemotherapy for BTCWhen compared with placebo and chemotherapy, durvalumab plus gemcitabine and cisplatin was superior in terms of overall survival in the treatment of advanced biliary tract cancer.
Latest:
Hereditary Renal Tumor Syndromes and the Use of mTOR InhibitorsA 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Latest:
Scratching the Surface in Managing Advanced RCCMatthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.
Latest:
CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple MyelomaPanelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
